Article ID Journal Published Year Pages File Type
2101441 Biology of Blood and Marrow Transplantation 2015 8 Pages PDF
Abstract

•Sustained hematopoiesis after double umbilical cord blood transplantation is from 1 donor unit, ie, single-unit dominance.•Literature review revealed only 11 patients with stable mixed-unit chimerism.•Clinical data for mixed-unit chimerism are scarce; enhanced graft-versus-leukemia effect is possible.•Mechanisms for single-unit dominance, intrinsic graft features, and graft-versus-graft immune interactions.•Understanding mechanisms of single-unit dominance may help improve patient outcomes

Double umbilical cord blood transplantation (UCBT) was developed as a strategy to circumvent the cell dose limitation of single UCBT with a concomitant potential benefit of lowering the rate of leukemia relapse. Sustained hematopoiesis after double UCBT usually is derived from a single donor unit, as only a few patients have been reported to display stable mixed-unit chimerism for varying periods of time. Explanations for the 1 unit dominance, predictors for identifying unit superiority, and persistence of long-term mixed-unit chimerism remain elusive. Review of published literature revealed only 11 of 280 patients (4%) with mixed-unit chimerism for at least 1 year after transplantation, with 3 patients receiving reduced-intensity conditioning regimens. Mixed-unit chimerism was more likely if both units were closely HLA matched to each other. Outcome data for patients with stable mixed-unit chimerism, for the most part, were scarcely reported. Analysis of the small sample size revealed a potential advantage of stable mixed-unit chimerism on enhancing the graft-versus-leukemia effect; however, definitive conclusions cannot be made on the effect of mixed-unit chimerism on the rates of graft-versus-host disease. Therefore, gathering outcome data prospectively in larger clinical series will help answer the question of whether stable mixed-unit chimerism is either beneficial and, therefore, should be strived for, detrimental and, thus, needs to be eliminated, or if it is of no clinical consequence.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Authors
, ,